Toggle navigation
Home
Search
Services
Blog
Contact
About
Phase I Clinical Trial Unit for Therapeutics Against Infectious Diseases: Evaluation of Therapeutics for MERS-CoV
Shumway, David
Dynport Vaccine Company, LLC, Frederick, MD, United States
Search 14 grants from David Shumway
Search grants from Dynport Vaccine Company, LLC
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Comments
Recent in Grantomics:
Your institution
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Manipulating Cutaneous Neuroimmunity to Treat Contact Dermatitis
GEMS, a Short-Term Summer Internship Program for Diverse Students
Osr transcription factors regulate embryonic lung development
Subcellular Origin of T-wave Alternans in the Beating Mouse Heart
Programs to Improve the Health, Education,and Well-Being of Young People.
Recently added grants:
Liver Xenotransplantation using CRISPR-modified Porcine Organs
Metabolomics Core
Host Factors in Response to Therapeutic Monoclonal Antibodies and Vaccination
Allergen T cell epitopes during the management of peanut allergic disease
Development of FRESH (Fast Rescue Employing Self-Helper virus) - a rapid, generalizable method to rescue infectious virus from noninfectious genomic material
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research and Development Contracts (N01)
Project #
272201500005I-1-27200003-1
Application #
9430351
Study Section
Project Start
2016-08-23
Project End
2017-04-30
Budget Start
Budget End
Support Year
Fiscal Year
2017
Total Cost
Indirect Cost
Institution
Name
Dynport Vaccine Company, LLC
Department
Type
DUNS #
014130053
City
Frederick
State
MD
Country
United States
Zip Code
21702
Related projects
Comments
Be the first to comment on David Shumway's grant
